The Lepu-backed genetic cancer therapy developer has completed a $94.9m round co-led by CICC Capital, Share Capital, Vertex Ventures China and Qianhai FOF.
Wuhan Binhui Biotech, a China-based genetic immunotherapy developer that counts oncology therapy developer Lepu Biotech as an investor, secured RMB600m ($94.9m) in series C funding on Wednesday.
CICC Capital, a private equity subsidiary of investment banking group China International Capital Corporation, co-led the round with private equity firm Qianhai FOF and venture capital firms Share Capital and Vertex Ventures China.
The round also featured Chongqing Linhou, Hua Fang Investment, HYfinity Investments, Infinity Group, Lapam Capital, Red Bridge Capital…
